Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-News: Epigenomics Appoints Thomas Taapken as New CFO, Effective April 1, 2011

Brings significant U.S. experience and strategic transactions 
expertise
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Personnel/Molecular diagnostics
Subtitle: Brings significant U.S. experience and strategic 
transactions expertise
Berlin, Germany, and Seattle, WA, USA, January 11, 2011 (euro adhoc) 
- Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer 
molecular diagnosis company, today announced Dr. Thomas Taapken as 
new Chief Financial Officer (CFO) succeeding the company's current 
CFO Oliver Schacht, PhD, effective April 1st, 2011. As previously 
announced in December 2010, Oliver Schacht will leave effective March
31st, 2011. Oliver Schacht and Thomas Taapken will work closely 
together to ensure an ordered and structured transition during Q1 
2011.
Taapken will join Epigenomics from Biotie Therapies Corp. (Finland), 
where he currently holds the position of CFO and is a member of the 
Executive Management Team. He was appointed to this position in 2008,
following a business combination between Biotie Therapies and elbion 
NV, where Taapken had been CFO since 2005. His extensive 
international experience in the life sciences industry includes 
further positions as Investment Partner at DVC Deutsche Venture 
Capital from 2003 to 2005 and San Francisco-based US venture capital 
firm Burrill & Company from 1998-2002. He also worked several years 
at Sanofi-Aventis in the United States and Germany, managing 
corporate venture capital activities, as well as in the areas of 
corporate & business development and research. Throughout his career,
he has been involved in numerous transactions spanning acquisitions, 
mergers, divestitures and as well as private and public offerings.
On his appointment as CFO of Epigenomics, Thomas Taapken commented: 
"I have been impressed with Epigenomics' transition from a 
biotechnology start-up into one of the most innovative cancer 
molecular diagnostic companies over the recent years, which is now 
aiming to become a major commercial player in the molecular 
diagnostic field. I very much look forward to contributing to its 
success during the important next phase of Epigenomics' corporate 
development."
Professor Dr. Rolf Krebs, Chairman of Epigenomics AG's Supervisory Board said:
"With Thomas' appointment, we have found the ideal CFO to bring Epigenomics to
the next level in realizing the full commercial potential of its groundbreaking
cancer diagnostics products. He brings in exactly the right skill set and
seasoned experience in the industry that we were looking for. He has an
outstanding track record of achievements in his previous positions and the
Supervisory Board believes he will be a great team contributor and driving force
in the Company's Management Team."
Geert Nygaard, Chief Executive Officer of Epigenomics added: "On behalf of the
entire Management Team I welcome Thomas as our new CFO. We share the same vision
of developing Epigenomics into a commercial success story in the cancer
diagnostics market and the addition of Thomas' transactional experience will be
instrumental in the continued development of the company. I look forward to
working with him."
Epigenomics also intends to strengthen its commercial operation in the US by
recruiting an experienced US-based marketing and sales executive to head the
U.S.-based operations, currently run by the departing CFO, and to lead the
transformation of that organization into a commercial molecular diagnostics
enterprise. With such an addition Epigenomics expects to be well-positioned to
drive its U.S. commercialization strategy.
-Ends-
Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368 
pr@epigenomics.com
www.epigenomics.com
About Epigenomics
Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests on the market and in development for 
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases, thereby potentially 
increasing the patient's chances of survival.
For development and global commercialization of IVD test products, 
Epigenomics pursues a dual business strategy in which direct 
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with 
broad customer access. Strategic diagnostics industry partners 
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics 
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc. 
for diagnostics test products and services, and QIAGEN N.V. for 
sample preparation solutions and research products.
The company is headquartered in Berlin, Germany, and has a wholly 
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more 
information, please visit Epigenomics' website at 
www.epigenomics.com.
Epigenomics legal disclaimer. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward-looking statements contained herein as a result of new 
information, future events or otherwise.
end of announcement                               euro adhoc

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG